Evidence map›Paper›PMID 27257501›Full record

ArticleNew microbes and new infections2015

Corrigendum to "The global threat of antimicrobial resistance: science for intervention" [New Microbes New Infect 6 (2015): 22-29].

I Roca, M Akova, F Baquero, J Carlet, M Cavaleri, S Coenen, J Cohen, D Findlay, I Gyssens, O E Heuer and 14 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in New microbes and new infections, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

I RocaISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
M AkovaDepartment of Medicine, Section of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey; ESCMID Executive Committee, Basel, Switzerland.
F BaqueroDepartment of Microbiology at the Ramón y Cajal University Hospital, Ramón y Cajal Institute for Health Research (IRYCIS), Division for Research in Microbial Biology and Evolution, CIBERESP, Madrid, Spain.
J CarletFondation Hôpital St, Joseph, Paris, France and World Alliance Against Antibiotic Resistance (WAAAR), Creteil, France.
M CavaleriEuropean Medicines Agency (EMA), London, UK.
S CoenenLaboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
J CohenBrighton and Sussex Medical School, Brighton, UK.
D FindlayGlobal Commercial Lead, GlaxoSmithKline (GSK), London, UK.
I GyssensDepartment of Medicine, Radboud University Medical Center and Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
O E HeuerEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
G KahlmeterClinical Microbiology, Central Hospital, Växjö, Sweden; ESCMID Executive Committee, Basel, Switzerland; EUCAST Steering Committee, Växjö, Sweden.
H KruseWHO Regional Office for Europe, UN City, Marmorvej, Copenhagen, Denmark.
R LaxminarayanCenter for Disease Dynamics, Economics and Policy, Washington, DC, USA; Princeton University, Princeton, NJ, USA.
E LiébanaScientific Unit on Biological Hazards, European Food Safety Authority (EFSA), Parma, Italy.
L López-CereroUnidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain.
A MacGowanDepartment of Medical Microbiology, Southmead Hospital, Bristol, UK; EUCAST Steering Committee, Växjö, Sweden.
M MartinsSchool of Public Health, Physiotherapy and Population Science, UCD Centre for Food and Safety, Molecular Innovation and Drug Discovery, University College Dublin, Dublin, Ireland.
J Rodríguez-BañoUnidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, and Departamento de Medicina, Universidad de Sevilla, Seville, Spain; ESCMID Executive Committee, Basel, Switzerland.
J-M RolainAix-Marseille Université, Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), Inserm, IHU Méditerranée Infection, Faculté de Médecine et de Pharmacie, and APHM, CHU Timone, Pôle Infectieux, Marseille, France.
C SegoviaInstituto de Salud Carlos III, ISCIII, Madrid, Spain.
B SigauqueCentro de Investigação em Saúde da Manhiça and Instituto Nacional de Saúde/Ministério de Saúde, Maputo, Mozambique.
E TacconelliDivision of Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Tübingen, Germany; ESCMID Executive Committee, Basel, Switzerland.
E WellingtonSchool of Life Sciences, University of Warwick, Coventry, UK.
J VilaISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain; ESCMID Executive Committee, Basel, Switzerland.

Funding

World Health Organization 001
6 · The paper itself

Abstract

[This corrects the article DOI: 10.1016/j.nmni.2015.02.007.].

Identifiers

PMID27257501
PMCPMC4877405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.